Skip to content
All posts

Journey Biosciences and Cardinal Health OptiFreight® Logistics Collaborate to Improve Long-Term Diabetes Care


Journey Biosciences, Inc., a biotechnology company with an innovative proactive diagnostic screening technology for diabetes-related kidney complications, today announced a collaboration with Cardinal Health (NYSE: CAH) OptiFreight® Logistics that will increase control and visibility across every transportation modality. Through this collaboration, Journey Biosciences will bring its flagship screening technology—NaviDKD—directly to the point-of-care, revolutionizing the way healthcare providers detect and manage long-term complications related to diabetes. By utilizing cutting-edge proprietary algorithms, this innovative solution enables proactive risk evaluation and testing, allowing healthcare professionals to take early action and improve patient outcomes.

"For years, diabetes has been a reactive conversation," said Adam Graybill, president and CEO of Journey Biosciences. “Healthcare providers have been challenged to react to what has already happened or is happening in real-time, including past test results, scores and levels. Our solution changes this conversation from reactive to proactive by delivering a solution specifically for DKD that allows healthcare professionals to eliminate or reduce risks by catching them early-on. Across diabetes management, Journey Biosciences sees fast, predictable product transport and delivery as an increasingly critical need, which is why we're excited to have OptiFreight® Logistics as part of our solution."

OptiFreight® Logistics delivers complete logistics management for the healthcare industry. As Journey Biosciences expands across the industry, OptiFreight® Logistics will provide customized logistics solutions with increased visibility for critical healthcare deliveries to enhance the diagnostic screening process.

"We're proud to partner with Journey Biosciences to help expand their critical work improving diabetes care," said Jonathan Kernya, director, Non-Acute – Cardinal Health OptiFreight® Logistics. "We believe in this mission and are confident our relationship with Journey Biosciences will strengthen the fight against a disease that has unique needs and, unfortunately, touches so many."

Journey Biosciences is on a mission to prevent and overcome preventable diseases, starting with the prevalent condition of kidney disease within the diabetes population. NaviDKD identifies the risk of diabetes-related kidney disease (DKD) years before signs or symptoms appear, enabling early intervention to prevent or delay the onset of DKD.

"As one of the industry's leading logistics providers, we're confident that OptiFreight® Logistics will enhance our ability to provide fast, predictable and accurate insights on patients' risk profiles for DKD and convenient lab screenings that fit into existing standards of care, creating an improved opportunity to expand the conversation about more proactive diabetes management and care," Graybill said.



About Cardinal Health OptiFreight® Logistics

Cardinal Health OptiFreight Logistics is a leading provider of total healthcare logistics. Using a comprehensive suite of tech-enabled, tailored solutions with access to committed experts, predictive data and analytics and innovative insights, OptiFreight® Logistics helps its customers gain control over freight spend and be prepared for what's ahead. With a legacy rooted in successfully navigating complex healthcare supply chains, it has saved its customers hundreds of millions in supply chain costs. For more information, visit

About Cardinal Health

Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at

About Journey Biosciences

Journey Biosciences is shifting the future of care through predictive innovations. Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass, offering up to 12 years of advanced diabetes-related kidney disease (DKD) detection and tailored intervention strategies. This groundbreaking approach improves patient outcomes, optimizes resource allocation, and reduces costs. Discover more about our transformative approach at

For media inquiries: